NCT03812523

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

A Randomized Phase II Study Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Southeastern Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Randomized Phase II study Comparing Lorcaserin versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Produced by Oxaliplatin

Detailed description

To examine lorcaserin a selective R-HT2c receptor antagonist approved by FDA as weight loss drug- for its ability to improve proprioceptive movements in patients with advanced colorectal cancer who developed neurotoxicity during oxaliplatin-based chemotherapy.

Conditions

• Chemotherapy-Induced Peripheral Neuropathy

Interventions

Type	Name	Description
DRUG	Duloxetine 60 mg qd	60 mg tablet Taken by mouth, Once Daily for 180 Days
DRUG	Lorcaserin	10 mg tablet Taken by mouth Twice Daily for 180 Days

Timeline

• Start date: 2019-06-01
• Primary completion: 2021-02-01
• Completion: 2021-10-01
• First posted: 2019-01-23
• Last updated: 2019-04-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study